IMMUNOVANT INC (IMVT) Stock News

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept...

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

Top 2 Health Care Stocks That May Collapse This Quarter

Roivant Provides Update on Graves’ Disease Development Program

Immunovant Provides Update on Graves’ Disease Development Program

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free...

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Investor webcast on Monday, September 9th at 8:00 a.m. ET...

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.

IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024

IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024.

IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunovant (NASDAQ:IMVT) just reported results for the fourth quarter of 2024.I...

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset...

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

The company says it's still running additional testing of the drug, calling the results "positive."

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.

Immunovant Awarded U.S. Patent for IMVT-1402

Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March...